Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

Market Cap	11.16B +94.9%
Revenue (ttm)	1.35B +0.9%
Net Income	274.30M +22.6%
EPS	1.58 +24.4%
Shares Out	174.35M
PE Ratio	40.50
Forward PE	36.79
Dividend	0.49 (0.76%)
Ex-Dividend Date	Jun 11, 2025

Volume	2,650,642
Average Volume	2,875,339
Open	63.65
Previous Close	64.68
Day's Range	63.28 - 66.83
52-Week Range	32.55 - 80.48
Beta	0.11
RSI	46.43
Earnings Date	Apr 22, 2026

About SHA:688513

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricarace...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 1,522
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688513

Financial Performance

In 2025, SHA:688513's revenue was 1.33 billion, a decrease of -1.36% compared to the previous year's 1.35 billion. Earnings were 284.06 million, an increase of 19.24%.